AI takes on lymphoma: personalized drug cocktail aims to outsmart cancer in older patients
NCT ID NCT07717177
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study tests whether an artificial intelligence (AI) system can help choose the best combination of drugs for older patients newly diagnosed with large B-cell lymphoma. Participants are first treated with a standard two-drug regimen (ZR2), then those at intermediate or high risk are randomly assigned to either continue ZR2 or switch to an AI-recommended regimen that may include up to five different drugs. The goal is to see if the AI-guided strategy improves how long patients live without their cancer progressing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of polatuzumab vedotin, rituximab, zanubrutinib, lenalidomide, and glofitamab, guided by an AI model
- What this could lead to
- If successful, this AI-driven approach could personalize treatment for older lymphoma patients, potentially improving survival and reducing side effects compared to standard therapy.
- What could go wrong
- This is a Phase 2 trial with a relatively small number of participants, so results may not apply to all patients. The AI model's predictions may not always be accurate, and the drug combinations carry risks of serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
Shanghai, 200020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope: drug may prevent dangerous reactions to cancer immunotherapy
- AI takes on lymphoma: personalized treatment strategy under trial
- Affordable CAR-T breakthrough: academic therapy offers new hope for blood cancer patients
- Immune cell therapy shows promise for aggressive blood cancer
- New hope for seniors with aggressive lymphoma: Four-Drug cocktail aims to spare chemo
- Experimental CAR-T therapy takes on tough lymphoma